Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors engaged.

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...